Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POLIVY vs AGRYLIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Polivy is an antibody-drug conjugate (ADC) composed of a CD79b-directed monoclonal antibody (polatuzumab vedotin) conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE). Upon binding to CD79b on B-cells, the ADC is internalized and MMAE is released via proteolytic cleavage, leading to cell cycle arrest and apoptosis.
Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.
In combination with bendamustine and rituximab for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior therapies.,In combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
Essential thrombocythemia (ET) to reduce elevated platelet counts and the risk of thrombotic complications
1.8 mg/kg intravenously every 21 days in combination with bendamustine and rituximab for up to 6 cycles.
Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.
The terminal elimination half-life of polatuzumab vedotin is approximately 12 days (range 8–20 days) for the antibody-drug conjugate. This supports a dosing interval of every 3 weeks. The half-life may be prolonged in patients with severe hepatic impairment.
Terminal elimination half-life: 1.3–1.5 days (31–36 hours) in patients with ET; allows twice-daily dosing.
MMAE is primarily metabolized via CYP3A4/5. Less than 10% is metabolized by other CYP isoforms (1A2, 2C9, 2D6, 2E1, 3A4).
Primarily metabolized by CYP1A2 to the active metabolite 3-hydroxyanagrelide, and to a lesser extent by CYP2C19 and CYP2D6.
Polivy (polatuzumab vedotin) is eliminated primarily through catabolism into small peptides and amino acids. The antibody-drug conjugate is not significantly excreted renally as intact compound; approximately <1% of the dose is excreted unchanged in urine. The majority of the drug is metabolized and eliminated via biliary/fecal routes, with approximately 80% of the total dose recovered in feces over 3 weeks, primarily as metabolites.
Renal: 80% (primarily unchanged drug), Biliary/Fecal: 5%
The conjugate is highly protein-bound (>97%), primarily to plasma proteins such as albumin. The free drug (unconjugated MMAE) is approximately 70–80% bound to albumin.
82–88% bound to plasma proteins (primarily albumin).
The volume of distribution at steady state is approximately 3.4 L (range 2.8–5.6 L), which corresponds to about 0.049 L/kg (assuming 70 kg). This small Vd indicates limited extravascular distribution, consistent with a large antibody-drug conjugate that remains primarily in the vascular space.
30–36 L (approximately 0.45–0.5 L/kg for a 70 kg adult); indicates extensive tissue distribution.
Bioavailability is 100% for the intravenous route. No oral formulation exists; the drug is administered only as an intravenous infusion.
Oral: 65–80% (median 73%)
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease.
No specific GFR-based recommendations; use with caution in renal impairment (Cr Cl <50 m L/min) and monitor closely.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate or severe hepatic impairment (Child-Pugh B or C).
Child-Pugh A: No adjustment. Child-Pugh B or C: Reduce initial dose by 50% and titrate cautiously.
Safety and efficacy not established in pediatric patients.
Children ≥7 years: 0.5 mg orally once or twice daily; adjust based on platelet response. Maximum: 10 mg/day. Not established for <7 years.
No specific dose adjustment recommended for elderly patients; monitor for increased toxicity, particularly infections and myelosuppression.
No specific adjustment; start at lower end of dosing range (0.5 mg twice daily) and monitor renal function and platelet counts closely.
No FDA black box warning.
None
Peripheral neuropathy: Monitor for new or worsening neuropathy; may require dose modification or discontinuation.,Infusion-related reactions: Premedicate with antihistamines and antipyretics; monitor during infusion.,Myelosuppression: Neutropenia, thrombocytopenia, and anemia; monitor blood counts regularly.,Infections: Increased risk of serious infections, including opportunistic infections.,Hepatotoxicity: Elevations of liver enzymes; monitor liver function.,Pneumonitis: Interstitial lung disease; monitor for pulmonary symptoms.,Tumor lysis syndrome: Monitor patients at risk and manage accordingly.,Embryo-fetal toxicity: Can cause fetal harm; advise effective contraception.
Cardiovascular risks: increased risk of ventricular tachycardia, QTc prolongation, and heart failure; use caution in patients with known cardiac disease.,Hematologic effects: monitor complete blood counts regularly due to risk of anemia, leukopenia, or thrombocytopenia.,Hepatic impairment: reduce dose in patients with moderate to severe hepatic impairment.,Renal impairment: use with caution in severe renal impairment.
Concomitant use with strong CYP3A4 inhibitors or inducers (avoid due to potential alteration of MMAE exposure).,Hypersensitivity to polatuzumab vedotin or any component of the formulation.
Severe hepatic impairment,Known hypersensitivity to anagrelide or any component of the formulation
No specific food interactions have been reported. Maintain adequate hydration. Avoid grapefruit or grapefruit juice if also taking certain CYP3A4 substrates, but no direct interaction with POLIVY.
Grapefruit and grapefruit juice should be avoided as they may increase anagrelide plasma concentrations. No other specific dietary restrictions; however, maintain adequate hydration to reduce risk of crystalluria.
Based on its mechanism of action as an antibody-drug conjugate targeting CD79b, POLIVY (polatuzumab vedotin-piiq) is expected to cause fetal harm when administered to pregnant women. There are no adequate and well-controlled studies in pregnant women. Verifies embryolethal and teratogenic effects in animal studies. The drug should be avoided during pregnancy, and women of reproductive potential should use effective contraception during treatment and for at least 3 months after the final dose.
Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies) at doses less than the human therapeutic dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. First trimester: Avoid due to organogenesis risk. Second and third trimesters: Unknown risks; consider alternative therapy.
There is no information regarding the presence of polatuzumab vedotin in human milk, its effects on the breastfed infant, or its effects on milk production. Due to the potential for serious adverse reactions in nursing infants, advise women not to breastfeed during treatment with POLIVY and for at least 3 months after the final dose. M/P ratio is not known.
It is not known whether anagrelide is excreted in human milk. No M/P ratio is available. Due to potential for serious adverse reactions in breastfed infants (e.g., thrombocytopenia, cardiovascular effects), advise women not to breastfeed during treatment and for at least 7 days after last dose.
No specific dose adjustment recommendations are available for pregnancy due to lack of pharmacokinetic data in pregnant women. The drug is not recommended for use during pregnancy. If treatment must be administered during pregnancy, use the standard adult dose based on body weight (1.8 mg/kg actual body weight) as a 90-minute IV infusion every 21 days in combination with other agents. Monitor for toxicity and consider dose modifications for adverse events per standard guidelines.
No specific pharmacokinetic studies in pregnancy. Pregnancy-induced plasma volume expansion may lower drug concentrations, potentially requiring dose adjustment to maintain therapeutic effect. However, due to teratogenicity risks, avoid use in pregnancy. If necessary, start at lowest effective dose (0.5 mg/day) and titrate based on platelet count monitoring, not to exceed 10 mg/day.
POLIVY (polatuzumab vedotin-piiq) is an antibody-drug conjugate targeting CD79b, used in combination with bendamustine and rituximab for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Monitor for infusion-related reactions, peripheral neuropathy, and myelosuppression. Pre-medicate with antihistamines and antipyretics. Avoid in patients with moderate to severe hepatic impairment.
Agrylin (anagrelide) is a phosphodiesterase III inhibitor used to reduce platelet counts in essential thrombocythemia. Monitor platelet count weekly during titration; target <600,000/µL. Avoid in patients with severe hepatic impairment (Child-Pugh C). Use with caution in cardiac disease due to risk of QT prolongation and arrhythmias. Anagrelide may increase bleeding risk, especially when combined with anticoagulants or NSAIDs. Discontinue 4-5 days before elective surgery.
This drug is given as an intravenous infusion; you may experience allergic reactions during or after infusion.,Report any numbness, tingling, or weakness in your hands or feet immediately.,You will have regular blood tests to monitor your blood cell counts and liver function.,Use effective contraception during treatment and for at least 3 months after the last dose.,Do not receive live vaccines while on this medication.
Take exactly as prescribed; do not skip doses or double up.,Report any signs of bleeding (easy bruising, nosebleeds, black/tarry stools) or palpitations immediately.,Avoid NSAIDs like ibuprofen and aspirin unless directed by your doctor.,Do not consume grapefruit or grapefruit juice while taking this medication.,Inform all healthcare providers (including dentists) that you are on anagrelide.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POLIVY vs AGRYLIN, answered by our medical review team.
POLIVY is a Antineoplastic Agent that works by Polivy is an antibody-drug conjugate (ADC) composed of a CD79b-directed monoclonal antibody (polatuzumab vedotin) conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE). Upon binding to CD79b on B-cells, the ADC is internalized and MMAE is released via proteolytic cleavage, leading to cell cycle arrest and apoptosis.. AGRYLIN is a Antineoplastic Agent that works by Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POLIVY and AGRYLIN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POLIVY is: 1.8 mg/kg intravenously every 21 days in combination with bendamustine and rituximab for up to 6 cycles.. The standard adult dose of AGRYLIN is: Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POLIVY and AGRYLIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POLIVY is classified as Category C. Based on its mechanism of action as an antibody-drug conjugate targeting CD79b, POLIVY (polatuzumab vedotin-piiq) is expected to cause fetal harm when administered to pregnant wome. AGRYLIN is classified as Category C. Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.